Purpose: This work aimed at studying the effect of L-carnitine on sperm parameters in the ejaculated semen and the cervical mucus, through a randomized, double-blind, placebo-controlled design, addressing idiopathic and varicocele cases.
Methods: Patients were randomized into two groups, one receiving L-carnitine and the other receiving placebo. Pretreatment and posttreatment semen and postcoital cervical mucus samples were evaluated and compared.
Results: Posttreatment semen samples showed that L-carnitine resulted in a statistically significant increase in sperm concentration in the cervical mucus in the study group compared with the placebo, although not in terms of motility or morphology, whether in the semen or in the cervical mucus. This effect was restricted to cases of idiopathic infertility and not in cases with varicocele, and to cases of oligoasthenozoospermia rather than cases with isolated asthenozoospermia.
Conclusion: L-Carnitine can have a positive effect on sperm concentration within the cervical mucus in cases of idiopathic oligoasthenozoospermia, possibly because of an enhanced cervical mucus penetration capability.
aDepartment of Andrology, Faculty of Medicine, Cairo University and bDepartment of Gynecology, Assisted Reproduction Unit, Al-Azhar University, Cairo, Egypt
Correspondence to Osama Shaeer, MD, 21 Gaber Ibn Hayan Street, Dokki, Giza, Egypt Tel: +20 233 359 047/+20 233 374 360; fax: +20 237 605 181; e-mail:email@example.com
Received August 23, 2011
Accepted September 25, 2011
Medical treatment of male infertility encompasses specific and empirical approaches. Specific approaches depend on treating the cause and involve a thorough patient appraisal. In contrast, empirical approaches do not address a specific pathophysiology and do not require accurate patient selection.
Whereas idiopathic male infertility comprises a large sector of male infertility cases 1, the main effective solution by far remains assisted reproduction, a costly option that does not resolve the original pathology. The search for the etiology and an effective treatment for idiopathic male infertility is still ongoing.
One of the medications proposed for treating male infertility is L-carnitine 2. This proposal was based on the fact that L-carnitine represents a cofactor in the transport of long-chain fatty acids inside the mitochondria and their subsequent oxidation, thereby providing the sperm with an energy substrate necessary for propulsion 3.
Several controlled and uncontrolled studies support a potential positive effect of therapy with L-carnitine and its acyl derivatives in treating male subfertility 4–10. However, Agarwal and Said 11 stated that although many clinical trials have been performed in this domain, the majority of these studies lack a placebo-controlled, double-blind design, making it difficult to reach a definite conclusion.
Spermatozoa in the semen use both glycolysis and fatty acid oxidation for generating energy. In contrast, sperm cells in the cervical mucus rely on fatty acid oxidation solely 3. As a cofactor in fatty acid oxidation, L-carnitine may be valuable in enhancing sperm activity in the cervical mucus, an understudied assumption.
This work aimed at studying the effect of L-carnitine on sperm parameters in the ejaculated semen and the cervical mucus, through a randomized, double-blind, placebo-controlled design, in cases of male infertility of various etiologies and seminal parameters of various forms.
The study was presented to and accepted by the internal review board beforehand. A written informed consent was obtained from each patient. Thirty infertile male patients were recruited, and randomized into two groups, one receiving L-carnitine (2 g/day, per oral) and the other receiving placebo for a period of 3 months. Both the investigators and the patients were blinded to the type of therapy administered. All patients provided written informed consents to the experimental nature of the study.
The selection criteria included an age range of 25–40 years (to exclude asthenozoospermia resulting from infrequent coitus in the older age groups) and primary infertility for two years. Selection criteria also entailed that semen analyses were to show asthenozoospermia repeatedly whether isolated or associated with other semen parameter disorders, in the absence of seminal antisperm antibodies and leucocytospermia. A scrotal Duplex study was used to exclude cases with abnormality in testicular size or echogenicity, and to determine the presence or absence of varicocele, excluding cases with grade III varicocele that would possibly indicate surgery rather than medical treatment. The female partners were to have normal ovulation, patent tubes, normal pelvic ultrasound, and favorable cervical mucus.
A 3-month washout period separated the onset of the study from prior therapy for infertility. Three serial semen analyses, 1 month apart, and a postcoital test preceded and followed treatment. The average of the three samples was adopted as the fertility status to avoid bias generated by the natural variations in semen parameters, a drawback in many studies in this domain. Pretreatment and posttreatment semen analyses and postcoital tests were compared in both groups. Analysis was performed according to the WHO guidelines 12.
Posttreatment semen analyses showed that L-carnitine therapy resulted in a nonsignificant increase in the mean concentration, immediate forward progressive motility, and 2-h forward progressive motility, and a decrease in the mean of abnormal forms, which was also nonsignificant compared with the placebo (Table 1).
In contrast, after treatment, the postcoital cervical mucus samples showed significant increases in the mean of the total sperm/high power field (HPF) compared with the placebo (Table 2). This significant positive effect of L-carnitine on sperm cells in the cervical mucus was reproducible in cases of idiopathic infertility (Table 3), in contrast to cases with varicocele (Table 4), where the findings were nonsignificant. No statistical significance was found for the effect on forward progressive motility and sperm morphology in the cervical mucus.
The significant positive effect of L-carnitine on sperm cell concentration in the cervical mucus was also reproducible in cases of oligoasthenozoospermia (Table 5), rather than cases with isolated asthenozoospermia (Table 6), where the improvement was nonsignificant.
In 1965, Marquis and Fritz 13 demonstrated that the epididymis contains an extremely high concentration of carnitine and that spermatozoa have a high activity of carnitine acetyl transferase, which is an effect of testosterone. Lenzi et al. 3 suggested the value of L-carnitine as a cofactor in the transport of long-chain fatty acids inside the mitochondria and their subsequent oxidation, thereby enhancing one of the two pathways for energy generation: fatty acid oxidation and glycolysis. Whereas epididymal spermatozoa use fatty acid oxidation for their energy metabolism, ejaculated sperms use the glycolytic process. In contrast, in the cervical mucus, lipids are an important energy source for sperms, and to metabolize these lipids, intrasperm L-carnitine is essential. Mazzilli et al. 14 thus reported the possible mechanism of action of L-carnitine as a sperm motility enhancer. In addition to the aforementioned, a secondary role of carnitine as an antioxidant 15 may add to its value in enhancing sperm cell function. Sperm cells take up relatively large amounts of carnitine during their epididymal transit. By the time spermatozoa reach the cauda epididymis, they have lost the ability to take up carnitine, but they now contain high concentrations of carnitine and acetyl carnitine and a high carnitine acetyl transferase activity 16.
Several studies supported a potential positive effect of therapy with L-carnitine and its acyl derivatives in male infertility 4–10. However, the issue remains controversial and open-ended due to contradictory results of those studies in addition to some methodological errors such as a lack of placebo controls in some and ignoring the natural spontaneous variations in semen parameters in others. These shortcomings were well documented by Agarwal and Said 11.
One of the controlled studies affirmed the efficacy of combined treatment with L-carnitine and L-acetyl carnitine in improving sperm motility, especially in patients with lower baseline levels 17. In contrast, Lenzi et al. 10 demonstrated that even though increases were seen in all semen parameters after carnitine treatment, they were nonsignificant, which is similar to our finding. In contrast, Sigman et al. 18 stated that carnitine supplementation demonstrated neither a significant nor a nonsignificant effect on sperm motility or total motile sperm concentrations in men with idiopathic asthenospermia.
On the scale of sperm-cervical mucus interaction, and in agreement with the current results, Mazzilli et al. 14 stated that a strict correlation was found between the L-carnitine content and the sperm motility in the cervical mucus.
The current study confirms the value of L-carnitine in enhancing sperm concentration in the cervical mucus by a double-blind placebo-controlled study, despite its nonsignificant effect on sperm parameters in the semen. In addition, this work is, to our knowledge, the first to demonstrate that L-carnitine therapy is effective in idiopathic, varicocele-free cases, with a resultant recommendation to restrict the use of L-carnitine to cases with idiopathic infertility.
In our study, cases with isolated asthenozoospermia had an associated varicocele; we therefore cannot confirm the inefficacy of carnitine in cases of isolated asthenozoospermia, but can confirm its value in cases of idiopathic oligoasthenozoospermia.
In our opinion, the enhancing effect on sperm concentration could be due to better cervical mucus penetration on account of better metabolism of the cervical mucus lipids as an energy substrate, despite an apparent lack of improvement of forward progressive motility that may be hindered by the nature of the mucus.
In conclusion, and according to the results shown, we recommend the utility of L-carnitine in the management of infertile men with idiopathic oligoasthenozoospermia.
Conflicts of interest
There are no conflicts of interest.
1. Cavallini G. Male idiopathic oligoasthenoteratozoospermia. Asian J Androl. 2006;8:143–157
2. Shang XJ, Wang XL, Huang YF. Progress of researches on carnitines in the clinical therapy of andrology. Zhonghua Nan Ke Xue. 2006;12:826–831
3. Lenzi A, Lombardo F, Gandini L, Dondero F. Metabolism and action of L-carnitine: its possible role in sperm tail function. Arch Ital Urol Nefrol Androl. 1992;64:187–196
4. Moncada ML, Vicari E, Cimino C, Calogero AE, Mongioi A, D’Agata R. Effect of acetylcarnitine treatment in oligoasthenospermic patients. Acta Eur Fertil. 1992;23:221–224
5. Costa M, Canale D, Filicori M, D’lddio S, Lenzi A. L-Carnitine in idiopathic asthenozoospermia: a multicenter study. Italian Study Group on Carnitine and Male Infertility. Andrologia. 1994;26:155–159
6. Vitali G, Parente R, Melotti C. Carnitine supplementation in human idiopathic asthenospermia: clinical results. Drugs Exp Clin Res. 1995;21:157–159
7. Vicari E, Calogero AE. Effects of treatment with carnitines in infertile patients with prostato-vesiculo-epididymitis. Hum Reprod. 2001;16:2338–2342
8. Vicari E, La Vignera S, Calogero AE. Antioxidant treatment with carnitines is effective in infertile patients with prostatovesiculoepididymitis and elevated seminal leukocyte concentrations after treatment with nonsteroidal anti-inflammatory compounds. Fertil Steril. 2002;78:1203–1208
9. Lenzi A, Lombardo F, Sgro P, Salacone P, Caponecchia L, Dondero F, et al. Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial. Fertil Steril. 2003;79:292–300
10. Lenzi A, Sgro P, Salacone P, Paoli D, Gilio B, Lombardo F, et al. A placebo-controlled double-blind randomized trial of the use of combined L-carnitine and L-acetyl-carnitine treatment in men with asthenozoospermia. Fertil Steril. 2004;81:1578–1584
11. Agarwal A, Said TM. Carnitines and male infertility. Reprod Biomed Online. 2004;8:376–384
12. WHO laboratory manual for the examination of human semen and sperm-cervical mucus interaction. 19994th ed Cambridge Cambridge University Press
13. Marquis NR, Fritz IB. Effects of testosterone on the distribution of carnitine, acetylcarnitine and carnitine acetyltransferase in tissues of the reproductive system of the male rat. J Biol Chem. 1965;240:2197–2200
14. Mazzilli F, Rossi T, Ronconi C, Germini B, Dondero F. Intra-spermatic L-carnitine and survival of sperm motility. Minerva Ginecol. 1999;51:129–134
15. Kobayashi A, Fujisawa S. Effect of L-carnitine on mitochondrial acyl CoA esters in the ischemic dog heart. J Mol Cell Cardiol. 1994;26:499–508
16. Casillas ER. Accumulation of carnitine by bovine spermatozoa during maturation in the epididymis. J Biol Chem. 1973;248:8227–8232
17. Balercia G, Regoli F, Armeni T, Koverech A, Mantero F, Boscaro M. Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertil Steril. 2005;84:662–671
18. Sigman M, Glass S, Campagnone J, Pryor JL. Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertil Steril. 2006;85:1409–1414
carnitine; cervical mucus; motility; postcoital; sperm